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April 12, 2011:1634–9it would be of great help if the authors would provide data on how
many patients had angina or ischemia (positive functional study) in
patients with ZES or PES restenosis.
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Reply
We thank Dr. Kaneda for his comments regarding our paper (1).
Although zotarolimus- and paclitaxel-eluting stents showed sim-
ilar angiographic results, the rate of target lesion and target vessel
revascularization was lower in the zotarolimus-eluting stent group.
The discrepancy between angiographic parameters and clinical
revascularization was also noted in the earlier REALITY (Head-
to-Head Comparison Between Cypher and Taxus) trial comparing
sirolimus-eluting and paclitaxel-eluting stents, in which the sig-
nificant differences in several continuous angiographic variables
(in-stent minimal luminal diameter, percentage of diameter ste-
nosis, in-stent late loss, and in-stent late loss index) did not
translate into significant differences in in-lesion binary restenosis
or in target lesion revascularization (2).
Although we do not fully explain this discrepancy between angio-
graphic measures and clinical outcomes, a plausible mechanism is
probably multifactorial. First, it might be possible that an angio-
graphically measured critical threshold inducing clinically or ischemia-
driven revascularization could differ among the different stent plat-
forms, even with similar angiographic parameters. It raises important
questions about the value of angiographic surrogate endpoints as
predictors of clinical outcome, as suggested in the literature (3,4).
Second, some difference in the incidence of the aggressive form (i.e.,
proliferative or total type) of in-stent restenosis (1.9% with zotaroli-mus stents and 0.5% with paclitaxel stents), which make it more
difficult for the treating physician to perform repeat intervention, thereby
favoring conservative medical treatment, might influence the rate of
target-lesion revascularization. Last, as suggested in other studies (5,6),
endothelial function of the implanted vessel according to different types of
DES could be a possible explanation for this discrepancy.
In the ZEST (Comparison of the Efficacy and Safety of
Zotarolimus-Eluting Stent with Sirolimus-Eluting and PacliTaxel-
Eluting Stent for Coronary Lesions) trial, as already defined, all target
vessel (or target lesion) revascularization was considered to be isch-
emia driven and clinically indicated if associated with a positive
functional study results, a target vessel (or target lesion) diameter
stenosis of 50% based on quantitative coronary angiography with
ischemic symptoms or a target vessel (or target lesion) diameter
stenosis of 70% with or without documented ischemia.
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Cardiac Magnetic Resonance for
Risk Stratification of Patients
With Frequent Premature
Ventricular Contractions
The study by Aquaro et al. (1) reported that abnormalities of the
right ventricle (RV) detected by cardiac magnetic resonance (CMR)
